Investors in RGNX can take the lead in REGENXBIO Inc. securities fraud lawsuit with …

Investors who have stakes in REGENXBIO Inc. (referred to as Regenxbio or the Company), listed on NASDAQ as RGNX, might have a chance to step up and take the lead in a securities fraud lawsuit with The Schall Law Firm. The lawsuit pertains to alleged violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 set forth by the U.S. Securities and Exchange Commission. The Plaintiff base for this lawsuit consists of investors who acquired the Company’s securities during the timeframe spanning from February 9, 2022, to January 27, 2026, known as the Class Period. In order to get involved in this legal process, investors are advised to reach out to the law firm before April 14, 2026.

The Schall Law Firm, which operates as a nationwide entity focused on safeguarding shareholder rights through litigation, stands ready to assist shareholders who may have experienced losses due to these alleged violations. Interested parties may get in touch with Brian Schall, located at 2049 Century Park East, Suite 2460 in Los Angeles, CA 90067. Mr. Schall can be reached by phone at 310-301-3335, or through the firm’s official website or email address. It is crucial to note that the certification of the class for this case has not yet taken place, so until that occurs, individuals will not be represented by an attorney. However, even without taking any immediate action, those affected by these events can still be considered as members of the class.

The crux of this class action lawsuit centers around the allegedly false and deceptive statements made by Regenxbio to the investing public. Specifically, the Company’s optimistic portrayal of its product candidate RGX-111 did not align with undisclosed negative information about its effectiveness and safety. The revelation of the discovery of an intraventricular CNS tumor in a participant involved in an RGX-111 study shattered the facade of positivity created by the Company. As a consequence, Regenxbio’s public statements during the class period are alleged to be inaccurate and significantly misleading. Once the truth about Regenxbio was brought to light, investors purportedly suffered financial losses as a result.

In light of these developments, affected investors are encouraged to participate in this legal action to seek recovery for their losses. The Schall Law Firm boasts a global clientele and possesses deep expertise in handling securities-related matters, making it a suitable ally for investors looking to pursue justice in response to alleged securities violations.